Next Article in Journal
Analysis of Site-Specific Methylation of Tumor-Related Genes in Head and Neck Cancer: Potential Utility as Biomarkers for Prognosis
Next Article in Special Issue
The Ever-Evolving Concept of the Cancer Stem Cell in Pancreatic Cancer
Previous Article in Journal
Colorectal Cancers: An Update on Their Molecular Pathology
Previous Article in Special Issue
Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy
Review

Contemporary Management of Localized Resectable Pancreatic Cancer

1
Department of Internal Medicine, University of South Carolina School of Medicine, Columbia, SC 29209, USA
2
Department of Medical Oncology, Mayo Clinic, Rochester, MN 55902, USA
*
Author to whom correspondence should be addressed.
Cancers 2018, 10(1), 24; https://doi.org/10.3390/cancers10010024
Received: 4 December 2017 / Revised: 16 January 2018 / Accepted: 18 January 2018 / Published: 20 January 2018
(This article belongs to the Special Issue Latest Development in Pancreatic Cancer)
Pancreatic cancer is the third most common cause of cancer deaths in the United States. Surgical resection with negative margins still constitutes the cornerstone of potentially curative therapy, but is possible only in 15–20% of patients at the time of initial diagnosis. Accumulating evidence suggests that the neoadjuvant approach may improve R0 resection rate in localized resectable and borderline resectable diseases, and potentially downstage locally advanced disease to achieve surgical resection, though the impact on survival is to be determined. Despite advancements in the last decade in developing effective combinational chemo-radio therapeutic options, preoperative treatment strategies, and better peri-operative care, pancreatic cancer continues to carry a dismal prognosis in the majority. Prodigious efforts are currently being made in optimizing the neoadjuvant therapy with a better toxicity profile, developing novel agents, imaging techniques, and identification of biomarkers for the disease. Advancement in our understanding of the tumor microenvironment and molecular pathology is urgently needed to facilitate the development of novel targeted and immunotherapies for this setting. In this review, we detail the current literature on contemporary management of resectable, borderline resectable and locally advanced pancreatic cancer with a focus on future directions in the field. View Full-Text
Keywords: pancreatic cancer; neoadjuvant therapy; R0 resection; gemcitabine; 5-fluorouracil; FOLFIRNOX pancreatic cancer; neoadjuvant therapy; R0 resection; gemcitabine; 5-fluorouracil; FOLFIRNOX
MDPI and ACS Style

Kommalapati, A.; Tella, S.H.; Goyal, G.; Ma, W.W.; Mahipal, A. Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers 2018, 10, 24. https://doi.org/10.3390/cancers10010024

AMA Style

Kommalapati A, Tella SH, Goyal G, Ma WW, Mahipal A. Contemporary Management of Localized Resectable Pancreatic Cancer. Cancers. 2018; 10(1):24. https://doi.org/10.3390/cancers10010024

Chicago/Turabian Style

Kommalapati, Anuhya, Sri H. Tella, Gaurav Goyal, Wen W. Ma, and Amit Mahipal. 2018. "Contemporary Management of Localized Resectable Pancreatic Cancer" Cancers 10, no. 1: 24. https://doi.org/10.3390/cancers10010024

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop